AbSci’s Promising Pipeline and Strategic Partnerships Drive Buy Rating

Morgan Stanley analyst Vikram Purohit maintained a Buy rating on AbSci (ABSI – Research Report) today and set a price target of $7.00.

Vikram Purohit has given his Buy rating due to a combination of factors that highlight AbSci’s promising future prospects. The company’s recent earnings report indicates that their pipeline programs are progressing as planned, with key milestones expected to be met in the coming years. Notably, the TL1A antibody program, ABS-101, is on track for a Phase I interim data readout in the second half of 2025, which is a significant catalyst for the company.
Additionally, there is active interest from potential partners regarding ABS-101, and AbSci aims to secure partnerships following the data readout, provided the terms align with their expectations. The accelerated timeline for the PRLR antibody ABS-201, with clinical development now expected to begin in early 2026, further strengthens the company’s growth outlook. These developments, along with a solid cash position that is expected to sustain operations into the first half of 2027, underpin Purohit’s positive outlook on the stock.

Purohit covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, Genmab, and Axsome Therapeutics. According to TipRanks, Purohit has an average return of -2.6% and a 37.32% success rate on recommended stocks.